Tizanidine Tablet
Product Images NDC 68071-5268

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 68071-5268). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5268 3)

Label for Tizanidine 4 mg oral tablets, manufactured by NuCare Pharmaceuticals, Inc. The label specifies a package size of 30 tablets and states each tablet contains 4.576 mg Tizanidine Hydrochloride USP, equivalent to 4 mg Tizanidine base. It includes product number P0598030 and indicates Rx only. The label features storage instructions to keep the product at controlled temperature between 59-86°F and a safety warning to keep out of reach of children. Manufacturer details include Dr. Reddy's Laboratories Limited in India and NuCare Pharmaceuticals in Orange, California.*

FDA Label Image

Fig1 (Fig1)

A line graph showing plasma concentration levels of Tizanidine (ng/mL) over time (hours from dosing) for different formulations and food conditions. The graph compares 2x4 mg Tizanidine tablets and capsules administered with and without food, illustrating the pharmacokinetic profile post-dosing up to 26 hours.*

FDA Label Image

Fig2 (Fig2)

A line graph showing improvement in Ashworth score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis measures improvement in Ashworth score, and the horizontal axis shows hours post-dose from 0 to 6. Both tizanidine doses show greater improvement than placebo, peaking around 2 hours post-dose.*

FDA Label Image

Fig3 (Fig3)

A line chart comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo groups at three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine group shows greater improvement scores than placebo, with error bars indicating variability.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride, showing the molecular arrangement of the active ingredient in the oral tablet formulation by NuCare Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.